Balance Sheet (Annual)

TSX:RBA / Ritchie Bros Auctioneers Balance Sheet shows account balances for the company at points in time. Balance Sheet data includes Assets, Current Assets, Fixed Assets, Property, Plant and Equipment (PPE), Inventory, Intangibles, Liabilities, Current Liabilities, Debt, Capital Lease Obligations, Common Stock, Retained Earnings, Treasury Stock, and Shareholders Equity.

All numbers are times 1,000 except per share units.

2015 2016 2017
  Cash And Cash Equivalents At Carrying Value 210,148 207,867 267,910
  Restricted Cash And Cash Equivalents At Carrying Value 83,098 50,222 63,206
  Accounts Receivable Net Current 59,412 52,979 92,105
  Inventory Net 58,463 28,491 38,238
  Other Assets Current - - -
  Income Taxes Receivable 2,495 13,181 19,418
  Assets Current 430,099 377,998 508,487
  Property Plant And Equipment Net 528,591 515,030 526,581
  Equity Method Investments 6,487 7,326 7,408
  Other Assets Noncurrent 3,369 4,027 24,146
  Intangible Assets Net Excluding Goodwill 46,973 72,304 261,094
  Goodwill 91,234 97,537 670,922
  Deferred Tax Assets Liabilities Net Noncurrent 13,362 19,129 18,674
  Assets 1,120,115 1,599,533 2,017,312
Liabilities And Stockholders Equity
  Auction Proceeds Payable 101,215 98,873 199,245
  Accounts Payable And Accrued Liabilities Current 120,042 124,694 164,553
  Accrued Income Taxes Current 13,011 5,355 732
  Short Term Borrowings 12,350 23,912 7,018
  Long Term Debt Current 43,348 - 16,907
  Liabilities Current 289,966 252,834 388,455
  Long Term Debt Noncurrent 54,567 595,706 795,985
  Other Liabilities Noncurrent 6,735 14,583 46,773
  Deferred Tax Liabilities Noncurrent 31,070 36,387 32,334
  Liabilities 387,971 903,753 1,263,547
  Contingencies - - -
Temporary Equity Carrying Amount Attributable To Parent - - 9,014
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
  Stockholders Equity
    Common Stock Value 131,530 125,474 138,582
    Additional Paid In Capital Common Stock 27,728 27,638 41,005
    Retained Earnings Accumulated Deficit 601,051 601,071 602,609
    Accumulated Other Comprehensive Income Loss Net Of Tax -57,133 -67,126 -42,514
    Stockholders Equity 703,176 687,057 739,682
Minority Interest 4,183 4,773 5,069
Stockholders Equity Including Portion Attributable To Noncontrolling Interest 707,359 691,830 744,751
Liabilities And Stockholders Equity 1,120,115 1,599,533 2,017,312

Peers - Business Services, Not Elsewhere Classified (7389)

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...